argenx SE (MEX:ARGX) Total Tax Payable : MXN279 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is argenx SE Total Tax Payable?

argenx SE's Total Tax Payable for the quarter that ended in Dec. 2024 was MXN279 Mil.

argenx SE's quarterly Total Tax Payable declined from Jun. 2024 (MXN256 Mil) to Sep. 2024 (MXN0 Mil) but then increased from Sep. 2024 (MXN0 Mil) to Dec. 2024 (MXN279 Mil).

argenx SE's annual Total Tax Payable increased from Dec. 2022 (MXN62 Mil) to Dec. 2023 (MXN74 Mil) and increased from Dec. 2023 (MXN74 Mil) to Dec. 2024 (MXN279 Mil).

argenx SE Total Tax Payable Historical Data

The historical data trend for argenx SE's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Total Tax Payable Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Tax Payable

Get a 7-Day Free Trial

69.56

88.52

62.02

73.57

279.26

argenx SE Quarterly Data
	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Tax Payable	Get a 7-Day Free Trial															73.57	-	255.51	-	279.26

argenx SE Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

argenx SE Total Tax Payable Related Terms

Thank you for viewing the detailed overview of argenx SE's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (MEX:ARGX) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGNF:USA ARGXb:UK 0QW0:UK 1AEA:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.